Within the last several years, there has been a marked shift in the treatment of AML from an intense/upfront chemotherapeutic approach for all patients to a more defined and targeted therapy based on specific disease features.
TORONTO (PRWEB) October 10, 2019
Advances in the treatment of acute myeloid leukemia (AML) have resulted in large part from improved molecular techniques, such as next-generation sequencing (NGS) which allows for the identification of specific molecular mutations within leukemic cells. The presence of such mutations not only provides prognostic information but may also function as the target(s) for anti-AML therapy.
On Wednesday, October 23, 2019 at 11am EDT (4pm BST/UK), join experts from Medpace in a live webinar where they will take participants through a case study on AML, a heterogeneous disease characterized by a spectrum of clinical and molecular features. Within the last several years, there has been a marked shift in the treatment of AML from an intense/upfront chemotherapeutic approach for all patients to a more defined and targeted therapy based on specific disease features.
Topics will include:
- Clinical: How mutation analyses in AML allow for prognostic classification and a targeted therapy approach
- Operational: Considerations for the execution of AML clinical trials in a competitive landscape
- Laboratory/Assays: How new standards for NGS-based treatment decisions and monitoring have to be further defined
Participants will hear from the following Medpace speakers:
- Patricia L. Kropf, MD, Medical Director
- Jeffrey Vassallo, PhD, Associate Director, Clinical Trial Management
- El Mustapha Bahassi, PhD, Associate Director, Clinical Laboratory
For more information or to register for this event, visit Challenges and Considerations For Clinical Development of Targeted Therapies in Acute Myeloid Leukemia.
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
Tel: +1 (416) 977-6555 ext 400